Search Results - "Rigal, Marthe"

Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer by Nunes, Toni, Pons, Thomas, Hou, Xue, Van Do, Khanh, Caron, Benoît, Rigal, Marthe, Di Benedetto, Mélanie, Palpant, Bruno, Leboeuf, Christophe, Janin, Anne, Bousquet, Guilhem

“…HER2-overexpressing metastatic breast cancers are challenging practice in oncology when they become resistant to anti-HER2 therapies such as trastuzumab. In…”
Get full text

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases by Angeli, Eurydice, Paris, Justine, Le Tilly, Olivier, Desvignes, Céline, Gapihan, Guillaume, Boquet, Didier, Pamoukdjian, Frédéric, Hamdan, Diaddin, Rigal, Marthe, Poirier, Florence, Lutomski, Didier, Azibani, Feriel, Mebazaa, Alexandre, Herbet, Amaury, Mabondzo, Aloïse, Falgarone, Géraldine, Janin, Anne, Paintaud, Gilles, Bousquet, Guilhem

“…Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause…”
Get full text

Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer by Monirul, Sanjana, Rigal, Marthe, Chouahnia, Kader, Le Jouan, Mélisande, Apparuit, Maxime, Paix, Adrien, Jacolot, Anne, Zelek, Laurent, Duchemann, Boris

“…In 2018, dosing regimens of the two most prescribed immune check point inhibitors (ICI), nivolumab (Opdivo ) and pembrolizumab (Keytruda ), in the treatment of…”
Get full text

Preliminary hazard analysis applied to outsourcing sterile chemotherapy preparations by Geraudie, Bastien, Kabiche, Sofiane, Rigal, Marthe, Malki, Myriam, Fontan, Jean-Eudes, Jacolot, Anne, Schlatter, Joël

“…Background Our hospital organization raised the possibilities of outsourcing their sterile pediatric chemotherapy preparations to another hospital conditional…”
Get full text

Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience by Rahmé, Ramy, Vidal, Valérie, Hueso, Thomas, Le Meur, Lucie, Rigal, Marthe, Ivanoff, Sarah, Brechignac, Sabine, Peffault De Latour, Regis, Gardin, Claude, Braun, Thorsten

“…Background: ELN 2022 risk classification of AML includes three risk categories and guides treatment choice. Adverse-risk patients, encompassing secondary…”
Get full text

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure by Harel, Stéphanie, Cherait, Amina, Berthon, Céline, Willekens, Christophe, Park, Sophie, Rigal, Marthe, Brechignac, Sabine, Thépot, Sylvain, Quesnel, Bruno, Gardin, Claude, Adès, Lionel, Fenaux, Pierre, Braun, Thorsten

“…Abstract Outcome of patients with high risk MDS and CMML who failed treatment with azacitidine remains poor with a median survival of 6 months, without…”
Get full text

A successful compartmental approach for the treatment of breast cancer brain metastases by Nguyen, Thuy T., Angeli, Eurydice, Darrouzain, François, Nguyen, Quang T., Desvignes, Céline, Rigal, Marthe, Nevine, Osman, Nicolas, Patrick, Le, Quang V., Winterman, Sabine, Pailler, Marie-Christine, Zelek, Laurent, Paintaud, Gilles, Janin, Anne, Bousquet, Guilhem

“…Background Brain metastases are challenging daily practice in oncology and remain a compartmental problem since most anti-cancer drugs do not cross the…”
Get full text

Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML) by Braun, Thorsten, Cherait, Amina, Berthon, Celine, Willekens, Christophe, Park, Sophie, Rigal, Marthe, Brechignac, Sabine, Harel, Stephanie, Thepot, Sylvain, Quesnel, Bruno, Gardin, Claude, Ades, Lionel, Fenaux, Pierre

“…▪ Outcome of patients with high risk MDS and CMML who failed treatment with AZA remains poor with a median survival of 5-6 months (Prebet; JCO 2011 29:3322)…”
Get full text